Precigen Gets FDA Clearance for IND Application for PRGN-3007 Tumor Treatment
October 26 2021 - 8:49AM
Dow Jones News
By Chris Wack
Precigen Inc. said the U.S. Food and Drug Administration has
cleared its investigational new drug application to initiate the
Phase 1/1b clinical trial of PRGN-3007 in advanced receptor
tyrosine kinase-like orphan receptor 1-positive hematological and
solid tumors.
The company said its PRGN-3007 is a first-in-class
investigational therapy based on the next generation of its
UltraCAR-T platform and incorporates intrinsic programmed cell
death protein 1 blockade.
This first-in-human study of PRGN-3007 will be conducted in
collaboration with the H. Lee Moffitt Cancer Center & Research
Institute.
The Phase 1/1b clinical trial is designed to evaluate the safety
and efficacy of PRGN-3007 in patients with advanced ROR1(+)
hematological and solid tumors.
Precigen shares were up 8% to $4.93 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 26, 2021 08:34 ET (12:34 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Precigen (NASDAQ:PGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Precigen (NASDAQ:PGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024